Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 3

See more details

Referenced in 2 patents
1 readers on Mendeley
  • Article usage
  • Citations to this article (8)

Advertisement

Research Article Free access | 10.1172/JCI116697

Intravenous infusion of tridocosahexaenoyl-glycerol emulsion into rabbits. Effects on leukotriene B4/5 production and fatty acid composition of plasma and leukocytes.

N Nakamura, T Hamazaki, K Yamazaki, H Taki, M Kobayashi, K Yazawa, and F Ibuki

First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Japan.

Find articles by Nakamura, N. in: PubMed | Google Scholar

First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Japan.

Find articles by Hamazaki, T. in: PubMed | Google Scholar

First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Japan.

Find articles by Yamazaki, K. in: PubMed | Google Scholar

First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Japan.

Find articles by Taki, H. in: PubMed | Google Scholar

First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Japan.

Find articles by Kobayashi, M. in: PubMed | Google Scholar

First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Japan.

Find articles by Yazawa, K. in: PubMed | Google Scholar

First Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Japan.

Find articles by Ibuki, F. in: PubMed | Google Scholar

Published September 1, 1993 - More info

Published in Volume 92, Issue 3 on September 1, 1993
J Clin Invest. 1993;92(3):1253–1261. https://doi.org/10.1172/JCI116697.
© 1993 The American Society for Clinical Investigation
Published September 1, 1993 - Version history
View PDF
Abstract

Leukotriene (LT) B4 is a major chemical activator of PMN. Inhibitory effects of oral administration of docosahexaenoic acid (DHA) on LTB4 synthesis by PMN are known. We intravenously infused tridocosahexaenoyl-glycerol (DHA-TG) emulsion into rabbits in three different doses, namely 0.8, 0.4, or 0.2 g DHA/kg, and investigated the changes in LTB4/5 production by ionophore-activated PMN. The averaged LTB4 production by PMN was significantly reduced to 57 and 59% of baseline at 6 h after the infusion of 0.8 and 0.4 g DHA/kg, respectively (P < 0.05), but not after the infusion of 0.2 g DHA/kg or 0.8 g soybean oil/kg. The combined concentrations of both DHA and eicosapentaenoic acid in the PMN phospholipid fraction were significantly increased at 6 h after the infusion of 0.8 or 0.4 g DHA/kg but not after the infusion of 0.2 g DHA/kg or 0.8 g soybean oil/kg. Oral administration of 0.8 g DHA/kg did not increase DHA or eicosapentaenoic acid in the PMN phospholipid fraction and did not decrease LTB4 production by PMN at 6 h after administration. We suggest that the infusion of 0.4-0.8 g DHA/kg might be beneficial to patients who suffer from diseases that are related to the acute elevation of LTB4 production.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1253
page 1253
icon of scanned page 1254
page 1254
icon of scanned page 1255
page 1255
icon of scanned page 1256
page 1256
icon of scanned page 1257
page 1257
icon of scanned page 1258
page 1258
icon of scanned page 1259
page 1259
icon of scanned page 1260
page 1260
icon of scanned page 1261
page 1261
Version history
  • Version 1 (September 1, 1993): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 3
  • Article usage
  • Citations to this article (8)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 2 patents
1 readers on Mendeley
See more details